---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-24-000005"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2024-01-23T23:59:59+00:00"
generated_at: "2026-06-06T20:05:38.191148+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# BeiGene appoints ex-Sanofi CEO Olivier Brandicourt to board; director Malley resigns

## Summary
- Thomas Malley resigned from BeiGene board and audit committee on Jan 22, 2024; no disagreement with company operations.
- Olivier Brandicourt, former Sanofi CEO and Blackstone Life Sciences Senior Advisor, appointed to board on Jan 23, 2024.
- Brandicourt will serve on audit committee and receive annual cash comp of $65,000 plus $17,500 for committee service, and pro-rated option valued at $400,000.
- He fills the vacancy created by Malley's resignation and will stand for election at the 2024 annual meeting in June.

## SEC filing metadata
- accession: 0001651308-24-000005
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2024-01-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000005/0001651308-24-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000005/bgne-20240122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-24-000005
- JSON: https://secwatch.observer/filing/0001651308-24-000005.json
- Plain text: https://secwatch.observer/filing/0001651308-24-000005.txt

## Key facts
- Executive change
  Olivier Brandicourt was appointed as Director at BeOne Medicines Ltd..
  - Action: appointed
  - Role: Director
  source text: On January 23, 2024, the Board appointed Olivier Brandicourt, M.D. to the Board to fill the vacancy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000005/0001651308-24-000005-index.htm
- Executive change
  Thomas Malley resigned as Director at BeOne Medicines Ltd..
  - Action: resigned
  - Role: Director
  source text: On January 22, 2024, Thomas Malley resigned from the Board of Directors (the “Board”) of BeiGene, Ltd. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000005/0001651308-24-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.